Zhou Daobin

[Expert Profile] Zhou Daobin, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in hematologic oncology in China, working in the Department of Hematology, Peking Union Medical College Hospital. He has long been dedicated to the clinical diagnosis, treatment, and scientific research of multiple myeloma, Waldenstrom's macroglobulinemia, lymphoma, and other hematologic malignancies, and is an important leading figure in hematologic oncology in China.

[Education & Career] Professor Zhou Daobin graduated from Peking Union Medical College, completed systematic clinical training in the Department of Hematology at PUMCH, and further studied at famous international hematologic oncology centers. He has long served as Director of the Department of Hematology at PUMCH, holding academic positions including member of the Hematology Branch of the Chinese Medical Association and Chair of the Hematology Branch of the Beijing Medical Association. He has presided over grants from the National Natural Science Foundation of China and the National Key R&D Program, and has accumulated profound academic achievements in the field of hematologic oncology.

[Areas of Expertise] Professor Zhou specializes in the diagnosis and treatment of multiple myeloma, Waldenstrom's macroglobulinemia, various lymphomas, and difficult hematologic malignancies. He has extensive experience in precise staging of multiple myeloma, standardized application of novel drugs (proteasome inhibitors, immunomodulators, monoclonal antibodies, CAR-T, etc.), and high-dose chemotherapy supported by autologous hematopoietic stem cell transplantation. He excels at managing advanced myeloma patients with "unbearable bone pain and recurrent infections," helping numerous patients achieve deep remission, prolonged survival, and improved quality of life.

[Academic Achievements & Industry Contributions] Professor Zhou has led a series of clinical studies on multiple myeloma and lymphoma, systematically evaluating treatment patterns and prognoses of Chinese patients in the era of novel drugs, with findings published in authoritative domestic and international journals. He has led the development of Chinese multiple myeloma diagnosis and treatment guidelines and expert consensus statements, actively promoted novel drug accessibility and standardized application, and led multi-center clinical trials and national hematologic oncology collaborative research, significantly improving the standardized diagnosis and treatment level of myeloma and lymphoma in China, and making important contributions to the development of hematologic oncology.

[Clinical Practice & Outstanding Contributions] Professor Zhou has long held dedicated hematologic oncology clinics, cumulatively treating tens of thousands of patients with multiple myeloma, lymphoma, and related conditions, with annual outpatient volume ranking among the highest nationwide. Leading his team, he has established a multidisciplinary collaborative diagnosis and treatment system for hematologic oncology, developing precise, individualized comprehensive treatment plans for countless patients. He is patient and meticulous with patients, excelling at selecting the most appropriate treatment path among complex conditions, and is deeply trusted by patients and respected by peers alike. He is a leading figure in the PUMCH hematologic oncology department.

[Honors & Reputation] Professor Zhou Daobin serves as Director of the Department of Hematology at Peking Union Medical College Hospital and Vice Chair of the Hematology Branch of the Chinese Medical Association, among other academic positions. He has presided over national-level projects including key grants from the National Natural Science Foundation of China, and is an authoritative expert in the field of hematologic oncology in China. He has profound expertise in standardized diagnosis, treatment, and innovative therapy of multiple myeloma, Waldenstrom's macroglobulinemia, and lymphoma. He has led multi-center clinical research on plasma cell disorders and lymphoma, promoted standardized application of targeted and immunotherapy, and participated in the development of multiple hematologic oncology diagnosis and treatment guidelines. For decades on the clinical front lines, he has helped numerous hematologic oncology patients prolong survival and improve quality of life, and is deeply trusted by patients and respected by peers alike.